Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Pharma-Bio Serv (PBSV) Total Liabilities (2016 - 2026)

Pharma-Bio Serv's Total Liabilities history spans 16 years, with the latest figure at $3.3 million for Q1 2026.

  • For Q1 2026, Total Liabilities fell 18.91% year-over-year to $3.3 million; the TTM value through Jan 2026 reached $3.3 million, down 18.91%, while the annual FY2025 figure was $1.7 million, 32.52% down from the prior year.
  • Total Liabilities reached $3.3 million in Q1 2026 per PBSV's latest filing, up from $1.7 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $5.1 million in Q1 2024 to a low of $1.7 million in Q3 2025.
  • Average Total Liabilities over 5 years is $3.5 million, with a median of $3.9 million recorded in 2023.
  • Peak YoY movement for Total Liabilities: plummeted 47.86% in 2022, then grew 29.79% in 2024.
  • A 5-year view of Total Liabilities shows it stood at $4.1 million in 2022, then decreased by 7.77% to $3.8 million in 2023, then tumbled by 31.74% to $2.6 million in 2024, then tumbled by 32.52% to $1.7 million in 2025, then soared by 90.34% to $3.3 million in 2026.
  • Per Business Quant, the three most recent readings for PBSV's Total Liabilities are $3.3 million (Q1 2026), $1.7 million (Q4 2025), and $1.7 million (Q3 2025).